Category: Views and analysis

  • Making sense of differing digital health funding reports

    Digital health venture funding had a ridiculous, bonkers, blockbuster year. On this, everyone can agree, although longtime watchers of the industry will remember that we’ve heard that consistently for the last several years. But never mind, 2021 was a blockbuster even compared to 2020 or 2019, with many sources saying there was twice as much, […]

  • Applied Virtual Reality in Healthcare: A comprehensive book on medical XR

    Walter Greenleaf, PhD, neuroscientist and digital health expert at Stanford University’s Virtual Human Interaction Lab, tells us about the new book Applied Virtual Reality in Healthcare: Case Studies and Perspectives and why he and his co-authors gathered insights from some of the most prominent figures in the field of medical extended reality (XR). Medical XR (ie, virtual […]

  • A multi-platform approach: the future of patient services

    Andy Graves and Dr Clare Moloney of IQVIA discuss how the COVID-19 pandemic accelerated the adoption of digital patient services and how future deployment alongside traditional methods could offer the best of both approaches. They outline how the momentum developed in the utilisation of digital solutions during this period can be built on to create […]

  • US vs EU: How can Europe translate home-grown innovation into biotech success?

    We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States. So, what can we do to keep home-grown science on European soil? From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial […]

  • Synthetic Control Arms – ambition to action

    Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions in investments, traditional clinical trial methods are increasingly a barrier to cost-efficient and timely drug development. Synthetic data is addressing this head-on by harnessing historical clinical trials […]

  • Utilising real-time data to improve customer engagement

    Oskar Möbert, Vice President OpenData Europe at Veeva Systems, tells us how they are reimagining customer reference data to boost pharma rep productivity, enable more personalised engagement, and increase patient reach. The medical landscape is generally becoming more complex, both in terms of the range of stakeholders involved in patient care and the rapid explosion […]

  • Digital therapeutics: a new frontier of medicine

    The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. To demonstrate how quickly the digital therapeutics space is developing, it is easiest to state that the first such therapy […]

  • Understanding the prevention and treatment needs for cardiovascular disease

    What does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) is Europe’s leading cause of death – not cancer, as many people would assume. Last year, over 60 million people in the EU – more than the population of Italy – were living with CVD. While there […]

  • Chronic kidney disease: treating a silent killer

    In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with AZ’s Joris Silon to discuss unmet needs in the condition. “Many times, I have talked to nephrologists who take care of patients with chronic kidney disease in the later stages, […]

  • Content metrics help generate compelling communication

    Companies seek efficiency and speed to market during the content creation process, review and approval cycles, and thus the collective time for content to be approved for distribution, says Ian Hale, vice president of commercial content at Veeva Systems. Gathering content metrics is key to ensuring superior performance during each step. ‘’Content metrics is the […]

  • The rise, acceleration and acceptance of telehealth adoption

    ‘Healing at a distance’ is the literal meaning of telemedicine. According to the World Health Organization, it is defined as the use of ICT to improve patient outcomes by increasing access to care and medical information, incorporating new advancements in technology and responding and adapting to the changing health needs and contexts of societies. Within […]

  • Don’t be afraid to change

    The digital revolution generated by the pandemic fractured lines of connection and severed the life-blood of being able to meet with clinicians for sales teams and MSLs. It created a fundamental shift in operating practice that has skewed product launches, sales and scientific communication but experts are advocating that companies embrace the change and use […]

  • CVS Health and Microsoft alliance: an example of an extended partnership

    Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees. David Rhew, MD, global chief medical officer and VP of healthcare at Microsoft, tells us, “Using Microsoft technology, CVS Health will develop a more agile, digital-first technology foundation.” […]

  • Targeted agents and immunotherapies

    Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Envision Pharma’s scientific solutions division lead Rebecca Goldstein, discusses this topic and other developments that cancer patients and their loved ones should be paying attention to. People with cancer and their caregivers have long been active participants in […]

  • Decentralised trials: beyond the pandemic

    The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic. Ben Hargreaves examines whether this adoption looks set to become a permanent feature of clinical trials moving into the future, rather than just supplying the tools to a temporary need. Decentralised clinical trials […]

  • The evolution of clinical trials: the pharmaphorum podcast

    In the latest episode of the pharmaphorum podcast, Dr Paul Tunnah speaks to head of Patient Engagement at Syneos Health, Marie Emms, and Elligo executive vice president and general manager of Worldwide Clinical Trials Early Phase Services, Keith Fern. Together they discuss the changing nature of clinical trials how COVID-19 impacted the sector, and the […]

  • Cutting through the Noise

    The pandemic has given us a surge of opportunities to take fresh looks at how we live, work and play with huge changes of pace and direction being funnelled through technology. Digital muscled its way to centre stage as we plunged into lockdowns and its life and sanity-saving qualities were immediately clear. It also helped […]

  • Life sciences predictions for 2022

    As the COVID-19 pandemic continues to impact the healthcare landscape, and the digital transformation of the life sciences industry gathers pace, what can we expect to see in 2022? In this webinar, senior members from Healthware Group discuss the key trends and developments set to shape the industry and present their predictions for the year […]

  • What HCPs think about mandatory vaccination

    What HCPs think about mandatory vaccination The practice of making vaccinations mandatory within a population has always been controversial. Historically, the first example of this was during the smallpox epidemic in the 1800s, when some European countries attempted to make vaccination against the disease compulsory. While it is hard to argue against the overall aim […]

  • Beyond the pandemic: the potential of mRNA technology

    The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Ben Hargreaves takes a look at how the space is currently progressing and in what direction it could be heading in future. The pandemic brought about an […]

  • Putting patient perspectives at the heart of kidney cancer research

    Kidney cancer is the 14th most common cancer, with approximately 400,000 new cases worldwide every year. Renal cell carcinoma (RCC) is by far the most prevalent type of cancer originating from the kidney, making up nine out of ten kidney cancer diagnoses. As chief medical officer, head of global medical affairs, patient safety and patient […]

  • Digital health innovation in 2022: Anticipating healthcare trends ahead of the J.P. Morgan week

    We spoke with Tanja Dowe, ahead of the annual  J.P. Morgan Health Care Conference 2022, about radical innovation in healthcare, including the potential of digital solutions to diagnose disease earlier, using digital therapeutics or preventive digital solutions more efficiently, and making use of technologies that result in accelerated drug discovery and development. “J.P. Morgan week […]

  • Nine for 2022: innovation and opportunities in healthcare

    In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on both pharma and healthcare issues, with themes we highlighted at the beginning of 2021 continuing their impact. Big Tech makes […]

  • Frontiers Health 2021

    Digital health is unlocking new avenues for innovation across life sciences, and industry leaders are keen to tap into the potential of this burgeoning area. At the 2021 Frontiers Health conference in Milan, thought leaders and industry experts from across the life science industry came together to discuss the future of digital in healthcare. In […]

  • Nine for 2022: International issues that are compelling, new or changed in 2022

    The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. Despite an estimated 9.25 billion doses administered globally by 4th January, with 25 different vaccines either approved for use or under emergency use authorisation, 2022 […]

  • AI providing the edge against cancer?

    The global R&D pipeline is dominated by potential treatments in oncology and this is also where the investment is flowing. This doesn’t look like changing moving into the future, the main challenge will be managing to use this money to create a proportionate number of approved treatments and ensuring an early diagnosis for patients in […]

  • Insights from the WHO’s Global Strategy on Digital Health event

    The World Health Organization (WHO) recently held a virtual panel discussion during Digital Health Week with speakers from around the world to talk about global strategy on digital health and collective opportunities for catalysing collaborative action. The panel focused on the objectives of the WHO’s Global Strategy on Digital Health 2020-2025, which aims to develop […]

  • Building internal strength

    Creating certainty in a landscape still convulsed by the pandemic is a lofty ambition, but pharma companies can use the disruption to develop positive internal change, as well as shoring up sales. While industry has variable influence over the reshaping of contacts with clinicians who have latched onto the benefits of telemedicine and virtual meetings, […]

  • Drug development and working with specialised Rare Disease networks

    There are currently an estimated 300 million people living with one or more Rare Diseases across the world. There are over 7,000 Rare Diseases that have been identified, yet only 5% have treatments. However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 […]

  • Leveraging augmented analytics to drive better business decisions

    In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not decades). Yet a successful COVID-19 vaccine gained emergency approval in just 11 months, a blistering pace that likely saved millions of lives. Such a fast turnaround […]

  • Focussing on pharma’s blind spot

    Industry’s free pass to its target audience has been shredded by the pandemic leaving the sales force compass struggling to find effective routes. It has exposed a blind spot that was previously covered by engagement success rates and comfortable repeat business. Only now are we seeing the downside of a lack of finesse along the […]

  • Deep Dive: Digital Health 2021

    There is no doubt that the COVID-19 pandemic has accelerated the adopt of digital health. As this issue’s contributors discuss, the rapid transition to digital has showcase the potential of technology across the industry, but how can we continue this momentum beyond the pandemic? Read on for a look at some of the biggest stories […]

  • Patient engagement processes: the pharmaphorum podcast

    This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman. Joining him to discuss the importance of patient engagement are Johnson & Johnson’s global patient engagement leader Katherine Capperella, Novartis’ head of patient engagement Mark Boutin, and […]

  • Digital Innovators: Wellthy Therapeutics’ Abhishek Shah

    Dr Paul Tunnah, pharmaphorum’s founder, continues his Frontiers Health Digital Innovator’s series by joining CEO Abhishek Shah live at Frontiers Health conference in Milan.  According to Abhishek, COVID allowed Wellthy to focus on areas in which it could genuinely have an impact, and the company evolved to become a platform that enables life science, & […]

  • From patient engagement to patient centricity

    Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon. But the difference between them is not like the choice between “agreeing” and “aligning” or “getting together later” and “taking this offline.” Going from the vital activity of patient engagement to the more encompassing state of […]

  • 2021: the year mRNA therapeutics came of age

    It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. One of its other scientific legacies was the specific development and approval of mRNA vaccines, the first in […]

  • Frontiers Health Digital Innovators: Orion Pharma’s Sammeli Likkanen

    pharmaphorum’s founder, Dr Paul Tunnah, continues his Frontiers Health Digital Innovators series by speaking with Orion Pharma’s director of digital medicine Sammeli Likkanen. Live from Frontiers Health conference in Milan, Sammeli provides insights into the difference between digital health and digital transformation. He discusses how virtual reality (VR) is changing digital therapeutics, and what Orion’s […]

  • Post-Brexit medicines regulation must have international scope

    Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind. If the UK creates regulatory frameworks that drastically diverge from those of its “science allies”, it could become a late – or even no – launch market for new treatments. The need for companies […]

  • Seizing opportunities with perfectly pitched messages

    Personal relationships have been the dominant force in sales for generations but the pandemic has ripped up this conveyer belt of convenience. More than 60% of clinicians are happy to either connect solely via technology or via a hybrid arrangement and there is no going back. The pharmaceutical industry became stuck in a groove of […]

  • Mind the gap: Are you delivering what HCPs value or what you want them to have?

    Since the onset of the Covid-19 pandemic, life science companies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). In the age of information overload, we all know that it is essential to add ‘value’ if we are to cut through the noise. And therein lies […]

  • Practice makes perfect

    The seismic shift away from face-to-face meetings caused by the pandemic has given the pharmaceutical industry a fundamental challenge around engaging with clinical staff. Sales representatives are finding it difficult to chisel out any personal time from doctors whose diaries are dominated by virtual connections. Every moment in front of a clinician is prized so […]

  • Digital health: the new normal?

    Personalised and tailored healthcare that utilises patient’s data is rapidly becoming a reality. Ben Hargreaves looks at the concrete steps already being taken by companies in the area. Amongst the many ways in which the pandemic has changed the way in which we live, one of the most common experiences for most people was to […]

  • The booming life sciences sector needs dynamic real estate support

    Bruntwood SciTech is the UK’s leading property provider dedicated to driving the growth of the science and technology sector. UK life sciences are buoyant with the success of the COVID-19 vaccine programme and a stream of innovation and investment marking it out for a starring role in the UK’s economic future. The government has pledged […]

  • How biomarkers and bioanalytics are changing R&D

    Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research. Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drug development in disease areas like non-alcoholic steatohepatitis (NASH) […]

  • 15 traits of effective bosses and how to catalyse your team

    Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at people manager effectiveness and how to boost team and co-worker engagement. It’s that special time in the annual corporate lifecycle: […]

  • Health literacy for the intellectually disabled: is pharma doing enough?

    What is health literacy and why is it important? Health literacy (HL), defined by the CDC as the degree to which individuals have the ability to find, understand and use information and services to inform health-related decisions and actions for themselves and others, is a valuable tool against health inequalities and negative patient outcomes. Low […]

  • Enabling the leaders of the future

    Janssen’s Mark Larsen, VP & Head of HR at Janssen EMEA, looks at what COVID-19 has taught us about good leadership and how we develop and enable the leaders of the future. COVID-19 has amplified what is expected of leaders in workplaces around the world. From clear communication with an unsettled, dispersed workforce to maintaining […]

  • Leveraging real-world data to meet payers’ needs

    Payers are becoming savvier in accepting real-world data. Certara’s Lee Stern and Shawn Bates discuss the challenges and how pharma can use real-world data to meet payers’ needs. For years, clinical trial data was king. But as healthcare costs continue to be squeezed, there is pressure on pharmaceutical companies to actually deliver on clinical trial […]

  • Health Innovators: Healthware Group’s Roberto Ascione

    pharmaphorum’s founder, Dr Paul Tunnah, continues his Health Innovators video series, in discussion with digital health visionary Roberto Ascione, from Healthware Group. In the first ‘in person’ video interview in the series, Paul speaks with Roberto live from the Frontiers Health conference in Milan, where he was again chairing the event and announcing the release […]

  • Time for a new model in patient access

    Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.   Why is a new access model so pressing, and has the pandemic accelerated the situation? Yes, it has. Although the need for a change in the […]

  • Reshaping events in pharma

    Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketing practices, including the digitisation of events. With medical conferences and events long a mainstay for pharma-HCP interactions, the pandemic’s travel restrictions, and lockdowns forced these in-person meet-ups to go virtual. […]

  • Time to take patient engagement to the next level

    Patient engagement in pharma is evolving, with some companies doing it better than others. Envision Pharma Group’s Dawn Lobban and Sarah Avent discuss the need to engage with patients at every level for holistic inclusion of the patient voice in order for pharma to become truly patient-centric. The Covid pandemic has sparked people’s interest in […]

  • Innovation and collaboration – the MHRA’s pandemic approach

    The pandemic has propelled issues for the pharmaceutical industry to the top of the political and public agenda, from clinical trial recruitment to the journey required for medicines or vaccines to reach patients. The public knows now more than ever that the Medicines and Healthcare products Regulatory Agency (MHRA) ensures the safety and quality of […]

  • Patients want to be heard. Is pharma listening?

    A common theme heard from the advocacy groups AXON works with is “Nothing for us without us,” says Natalie Turner, director at AXON, a global healthcare communications agency. Patients want to be part of the healthcare conversation and genuinely heard by those who make the final decisions, but pharma does not always understand how to […]

  • Three views on technology improving clinical trial efficiency

    Marie Emms, vice president of site and patient participation at Syneos Health, tells us technology helped increase patient enrolment, improve diversity and inclusion, and boost retention rates for clinical trials after the pandemic. Still, she says a lot needs to be done to continue this upward trajectory. “There’s an acknowledgement among companies that the paradigm […]

  • Emerging from the shadow of COVID-19

    We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos. In the biotech industry, if you are not motivated by helping patients and potentially transforming their lives, then you’re in the wrong job. Yet understanding what people go through on their journey – particularly those living with a […]

  • Novo Nordisk on seeking partnerships to expand its portfolio

    Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’s senior VP of global drug discovery Karin Conde-Knape. She discusses which therapeutic areas the company is gaining momentum in and how it aims to build its presence […]

  • Legal requirement, ethical duty: How to develop compliant, useful lay summaries

    New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year. Patient involvement is key, they say. The sooner patients are involved in developing and publishing lay summaries, which will soon be a legal requirement in the European Union, the better. That was […]

  • Consumer health innovation – where passion and science meet

    Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. After making her way from early-stage drug development research to her current role, […]

  • Getting better at measuring international uptake of medicines?

    In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring international uptake of medicines. The publication of a new report from healthcare analytics firm LOGEX, with the Institute for Rational Use of Medicine (IVM), on uptake in England should provide plenty of food for thought for the […]

  • One world, one health: The interconnected web of antimicrobial resistance

    Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data. AMR threatens to undermine “almost a century of health gains” and marshalling a response to such a problem “requires cooperation at many levels”. That’s according to a newly published report from the […]

  • Oncology treatment decisions aren’t just based on clinical data

    Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the last decade. Yet how many other therapy areas have market leaders that don’t even have clinical approved indication in that indication? Join this Cerner Enviza webinar, held in partnership […]

  • Sales coaching: preparing for the new reality in pharma

    COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The pandemic’s first effects on pharma sales were swift and immediate, as lockdowns were put in place […]

  • Leveraging multichannel and multimedia in HCP education

    COVID has forced the pharma industry to step up and take a more innovative approach to the channels and content it uses to reach and engage with HCPs, says Chloe Prince, account director at EPG Health. In the face of the pandemic, pharma companies are adapting traditional methods of customer engagement, as well as adopting […]

  • Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

    In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars. They look at how biosimilars are changing healthcare and what the market looks like today, as well as Sandoz’s involvement in the area and the company’s future plans in […]

  • Janssen on driving R&D innovation with data science

    The amount of patient data has skyrocketed, providing opportunities to gain a deeper understanding of diseases that are particularly complex or areas with a high level of unmet need, according to Janssen’s Najat Khan. She discussed the implications of this direction of travel for pharma, and some of the changes she’s seen in data science […]

  • Using bispecific antibodies to advance cancer immunotherapy

    Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Bispecific antibodies (bsAbs) are designed to recognise two different epitopes and, compared to current monovalent antibody therapeutics, bsAbs have enhanced binding, specificity, and efficacy, making them exciting candidates for more targeted cancer treatments. In 2019, there were […]

  • Patient engagement strategies: the pharmaphorum podcast

    This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate. Here he takes a helicopter view of patient engagement in a discussion with MSD’s European lead for patient innovation Paul Robinson, that’s moderated by pharmaphorum’s former […]

  • Deep Dive: Patients and Partnerships

    As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients. In this issue there are insights from Astellas and Alnylam, plus informed commentary on health literacy, patients’ role in the healthcare conversation and we also look at R&D innovation in areas […]

  • Speak like a leader: 15 secrets to engage any audience

    Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post on delivering a seemingly effortless talk also incorporates select insights from Executive Speaking Success’ John Bates. Public speaking is the original human communication […]

  • Sustained healthcare systems need sustainable pharma business models

    COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing. But can the Pharmaceutical Strategy for Europe help to redress the balance? Only sustainable, robust supply chains and business models will allow innovation to flourish, secure access to medicines, and minimise the industry’s impact on the environment. […]

  • Health Innovators: Healios’ Richard Andrews

    In the latest Health Innovators video chat, pharmaphorum’s founder, Dr Paul Tunnah, chats with the founder and CEO of digital mental health pioneer Healios. Rich Andrews explains his background in big pharma and his inspiration for moving into the start-up space with Healios and its focus on mental health and neurodiverse conditions for children and […]

  • How are the European pharma and biotech sectors addressing strategic communications?

    Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna Campbell-Gray. Consumers are driving and accelerating change when it comes to healthcare, demanding better, faster and more accessible services. The COVID-19 pandemic has further altered the dynamics for this sector […]

  • What HCPs think about medical tweetorials

    Twitter has been used by health professionals for over a decade to share medical knowledge and education. Until late-2018 they had only 140 characters to do this, increasing to 280 at that time. There have been some collaborative ways to have meaningful interactions on the platform including Twitter journal clubs. Four ways HCPs are using […]

  • BMS’ Catherine Owen: Hybrid communication is here to stay

    The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation. The core of Bristol Myers Squibb’s commercial business outside its home base of the US covers most of the large countries in Europe, as well as Canada and Japan. These 19 […]

  • A Life in a Day by The Method

    Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in a patient-centric way can be challenging. The Method is an innovative learning and development company delivering a ground-breaking programme designed to achieve tangible patient-centric results within pharma and healthcare The […]

  • Make locally led public health ‘business as usual’, says report

    COVID-19 proved the value of locally led, place-based public health – but teams need long-term funding and support if they are to take their place as an essential cog in the ICS machine. Local public health teams have been acting as “linchpins” during the pandemic, building cross-sector relationships to respond to the immediate crisis, as […]

  • COVID-19 has propelled the regulatory industry years ahead

    Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape. In my 26 years of industry experience, I’ve often found the regulatory process to have  plenty of opportunities to become more efficient and faster. When the COVID-19 pandemic hit, it lit a fire under the regulatory […]

  • Translating EU presence to US market success

    Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national and state requirements and regulations, says Two Labs’ Howard Miller. As the world’s largest single pharmaceutical market, the US should – at least at first glance – provide a simplified […]

  • BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast

    Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and communications. As part of that we looked at how she approaches the 19 markets she oversees and the challenges that can present. And Catherine suggests some areas […]

  • Navigating the patient maze – pharma’s evolving challenge

    Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, putting it at the heart of commercial strategies. It’s a hard task to get right though, as ICON’s Chris O’Toole explains, but the rewards can be huge on both sides. […]

  • What does the future of European healthcare look like?

    After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long term? COVID has taught us that future proofing healthcare systems has to be everyone’s main priority in the coming years. That’s according to the speakers at a roundtable session, held as part of the Reuters Events: Pharma […]

  • Launch excellence: escaping the complexity trap

    IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world. Launching a new product is an inherently complex endeavour. It requires planning, alignment and execution across multiple organisational boundaries, while new products face an increasingly complex launch environment. It is precisely this complexity that makes it […]

  • It’s time to rethink the physician-pharma relationship

    The traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience – prescribing physicians. What happens when suddenly that form of interaction is taken away? Michael Brandreth, group vice president at WebMD Global, tells us how the events of the last 18 months make it more important than […]

  • Refining digital collaboration

    Pharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward intersecting health and technology. Natalie Yeadon, Co-founder and CEO of Impetus Digital, tells us how COVID has accelerated digital health transformation and made effective virtual collaboration more important than ever. […]

  • ‘Build back better’ cannot mean longer waiting times for change

    Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients in the UK. If the COVID-19 pandemic has shown us anything, it has highlighted the extent to which health inequity plagues our society. Although the Government, public and health care system have started to wake up to […]

  • Preparing for a pandemic starts with creating a mentally resilient society

    Janssen UK & Ireland’s managing director Gaëtan Leblay discusses the importance of maintaining the spotlight on our mental health post-pandemic, and why we must hone our mental resilience for possible future health crises. Our day-to-day life now looks significantly different compared to two years ago – without question, the pandemic has affected us all. One […]

  • Closing pharma’s communication gap with patients

    The pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied by real change in the way product development is carried out. Keri McDonough thinks there is still a still a void between some pharma and patients, but one that can be bridged by developers who make a […]

  • Valuable virtual tools to keep HCPs informed

    If there’s one take-home message about working during a pandemic, it is the enormous value that virtual events, webinars and e-learning can bring when face-to-face meetings and presentations are impossible. COVID-19 raised the profile of these digital interactions, becoming a key resource for pharma during the pandemic almost overnight and leaving companies scrambling to develop […]

  • Evidence, investment, scale: the route to digital health adoption

    Digital health tools hold huge potential, and the evidence base is growing all the time – so what is holding us back and how does the sector overcome the multiple barriers to widespread adoption? We are living through a digital health revolution, and the pace of change has been accelerated by the COVID-19 pandemic. More […]

  • Leveraging a strong product launch to build a successful pharma brand

    So much effort goes into ensuring the successful launch of a new pharmaceutical product or indication, but it’s only once that has been achieved that the real work begins, says Align Strategy’s Christine Fletcher. Introducing a new pharmaceutical brand is akin to asking someone to change their established habits, and first impressions of that treatment […]

  • Transform patient experience with intelligent hyper-personalisation

    Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave of digitisation in the healthcare industry. As part of these efforts, customer experience (CX) became a key focus area to ensure customer engagement and loyalty. Significant strides have been made […]

  • The ‘patient of the future’ is driving radical innovation in healthcare

    Digital data collection, utilisation of real-word data and patient-centric thinking will all contribute to the rapid development of a new healthcare landscape, says Debiopharm Innovation Fund’s Tanja Dowe. In recent years, we have seen thinking shift from focusing on a disease’s treatment to seriously considering the wider potential for its prevention, enabled by dramatic advances […]

  • Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast

    Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations. Amit’s the global head strategy and operations and local markets manufacturing at Novartis Technical Operations and discussed how his company ensured an uninterrupted supply […]

  • The post-pandemic evolution of pharma-doctor digital interactions

    M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19. COVID-19 forced an unprecedented shift towards the virtual delivery of healthcare, suddenly compelling doctors increasingly to use digital means to care for their patients. As healthcare resources and delivery were prioritised, […]

  • Deep Dive: Communications and Commercialisation

    The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. In some cases it was an accelerant for existing plans, but it has also caused some new shifts in the landscape, shifts that have yet to be completed. This issue assesses European pharma’s approach to strategic […]

  • Blood Cancer UK: Hopes for our community’s future in the time of COVID

    This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains the need for better awareness and understanding of this common, but less-understood disease. Blood cancer is the fifth most common cancer in the UK and the third most deadly, killing […]

  • Developing case-based content to engage HCPs

    In this instalment of EPG Health’s HCP engagement series, Georga Cottle discusses how case-based learning connects medical theory to medical practice. Medical education doesn’t stand still. The acute demands on today’s healthcare systems require ever-more effective learning opportunities for healthcare professionals (HCPs) and offer pharma companies valuable chances to support evidence-based clinical practice. One of […]

  • Top email calamities to avoid … and how to make an impact instead

    Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. In this column he addresses the appropriate use of email and how to avoid nightmares in electronic communication. “My fiancée had bought me a […]

  • Health Innovators: Sidekick Health’s Saemundur “Sam” Oddsson

    As pharmaphorum’s founder, Dr Paul Tunnah, continues his Health Innovators video series, he connects with the co-founder of Iceland’s Sidekick Health, Saemundur “Sam” Oddsson. They discuss Sam’s journey from being a medical doctor to co-founder of a digital health company and some of the learnings along the way. Sam explains the purpose of Sidekick – […]

  • Treatment for all: the key steps to better representation in pharma

    As people have become more conscious and vocal about diversity and inclusion, Page & Page’s Lisa Lishman says pharma should reassess how it conducts clinical trials. The pharmaceutical industry is one of the most important industries in the world, providing lifesaving drugs and treatment to people who need it the most. This already significant industry […]

  • Early detection of cancers will require blood sweat and tears

    An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell. The announcement that the NHS is taking part in a major new clinical trial for a blood test that could detect more than 50 cancers early has been welcomed as a […]

  • Virtual engagement and collaborations: the pharmaphorum podcast

    As the world passes the year and a half mark of the COVID-19 pandemic, the evolving ‘new normal’ experience across the healthcare sector has brought huge changes to the way pharma engages healthcare professionals. Joining the pharmaphorum podcast to discuss these changes is Impetus Digital’s co-founder and CEO Natalie Yeadon, in a special episode sponsored […]

  • The benefits of being a family-run pharma company

    The third generation of his family to hold a leadership role at Chiesi Group, Giacomo Chiesi reflects on the lessons he learned from his father and grandfather – and from his work as a former management consultant – about what it means to run a successful family business and its benefits. Family businesses across industries […]

  • Addressing the HIV epidemic in Eastern Europe and Central Asia

    Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021 marks 40 years since the first cases of HIV were reported. In that time, over 79 million people have been diagnosed with HIV, with more than 36 million dying from AIDS-related illnesses, more than any other infectious […]

  • It’s time to do better for patients with rare neurological disorders

    Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare CNS conditions. Rare diseases impact more than 30 million Americans, and 400 million people around the globe. Less than 5% of the more than 7,000 rare diseases have approved treatments. […]

  • The post-COVID future of physician sample access and engagement

    Building modern commercialisation strategies requires pharma to find the right balance of old ways and new approaches, says Cardinal Health’s Jennifer Baughman. COVID-19 has fundamentally changed much of our lives – from how we interact with people to how we work. For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies […]

  • Taking stock of NHS medicines optimisation

    Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at local level, says NHS Gloucestershire CCG’s Ellen Rule. Medicines optimisation aims to improve health outcomes, service quality, and sustainability by ensuring patients are taking […]

  • EFPIA: Partnership is the key to healthcare’s biggest challenges

    The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen, Novartis and more. Partnership is the key to unlocking the solutions to our major healthcare challenges, and “no player has a monopoly on good ideas”. That’s according to the European Federation of Pharmaceutical […]

  • The tech revolution reshaping European healthcare

    The European health tech industry has made a “quantum leap” into using digital health technology due to the pandemic with the help of a growing number of trailblazing entrepreneurs, according to AlbionVC. The London-based venture capital firm provides a useful overview of how healthcare has changed over the last decade, and where digital health is […]

  • France’s biotech ecosystem is primed for growth – it’s time to feed it

    After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. Prior to the pandemic, our homegrown entrepreneurs felt too often they had to go abroad to the United States to get the funding they needed, government support for clinical trials […]

  • Preparing for a post-pandemic world

    Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the pandemic. There’s plenty of talk about a post-COVID world right now, which can seem strange when so many places are still feeling the impact or remain in the grip of […]

  • Biotech Insight podcast: Overcoming planning challenges in oncology

    The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology. Joining Dominic Tyer for this instalment of Biotech Insight are Prithu Somani, senior manager of forecasting and business analytics at Genmab, and Kantar Health’s vice president of […]

  • 4 ways emerging pharma companies can harness marketing content

    Rapid creation of compliant marketing content is increasingly important and there are ways emerging pharma companies can stay ahead of the game – despite having fewer resources than bigger firms. A new pharma marketing content ebook from Veeva looks at best practices for building a content foundation that can enable long-term growth. It explains how […]

  • How blockchain can revolutionise medical records and save lives

    Balancing medical privacy with ease of access for healthcare professionals is a challenge, but technology could provide the solution, says Aleph Zero Foundation’s Matthew Niemerg. Most people don’t think of healthcare when they hear blockchain, and that’s understandable; the technology so far hasn’t gone much beyond financial instruments – at least, not in the eyes […]

  • Prof Nigel Osborne: Science is catching up with ‘medical music’

    The internationally recognised composer, peace worker and musical therapy pioneer tells pharmaphorum how his emerging field stands at an important threshold. History provides a wealth of commentary on the emotional value of music. One of the earliest came from Plato, who concluded that “rhythm and harmony find their way into the inward places of the […]

  • Targeting COVID-19 and cancer with immunotherapy advancements

    Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections. Monoclonal antibodies (mABs) are highly specific therapies associated with […]

  • How pharma can help the post-COVID recovery of European cancer care

    The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered. The publication, which has been supported by Accord Healthcare, also provides a series of […]

  • External control arms and debunking real-world data myths

    For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies to patients faster, say COTA Viraj Narayanan and Karla Feghali from ConvergeHEALTH by Deloitte. External control arms (ECAs) – also known as synthetic control arms – are based on real […]

  • Nine ways to keep focus and boost your pharma career

    Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. His second column addresses the vital importance of prioritisation. There used to be times when every single task seemed important. Naturally. I’m a perfectionist […]

  • Amplifying the patient voice for better engagement, recruitment and retention

    Everyone is familiar with the phrase ‘patient-centricity’ but, where it might once have been seen as a ‘checkbox exercise’, it has gained preeminent status in the era of COVID-19, says Prime Global’s Ross Jackson. The pandemic has transformed many aspects of our industry and one area that change has come to is patient engagement within […]

  • Improving access to treatments in challenging markets

    The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at pace and speed. Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute […]

  • Blueprints for UK pharma-NHS joint working

    Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As the NHS begins to recover from the biggest crisis in its history, the biopharmaceutical industry is stepping up to the plate to offer its support and a new online repository of […]

  • Vertex’s Nicola Massey: the pharmaphorum podcast

    In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland. Having joined the biopharmaceutical company only fairly recently, they discuss her career path to Vertex, and also what it was like to join virtually – something that’s Increasingly common for many people […]

  • Organon Makes Women’s Health a Priority

    Simon Nicholson tells us how Organon, a new women’s healthcare company, is working to effect positive change globally by listening to women about their health care needs and allowing that information to drive their business development strategy. As Merck looked to expand its portfolio, it was determined that there’s a huge problem and need, particularly […]

  • Does draft RCT guide set the scene for future trials?

    A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter what they do or where they are based. The Good Clinical Trials Collaborative (GCTC) has published a draft guidance document, and is asking for the life sciences sector to make […]

  • Health Innovators: PureTech Health’s Daphne Zohar

    In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They discuss the publicly-listed biotech’s pipeline projects and focus on the BIG (brain-immune-gut) axis as well as PureTech’s interest in digital therapeutics. Daphne explains how she built an impressive team of board […]

  • From start to finish – digitising clinical trials

    Over the past two years, the pharma industry’s demand for automated research solutions has increased significantly and, particularly when it comes to clinical trial design, the need has never been greater. This shift to digitised approaches has been triggered by some persistent challenges faced by those companies still reliant on applying manual processes. “A few […]

  • Organicell on regenerative medicine: the pharmaphorum podcast

    In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative Medicine. They looked at the development of regenerative medicine and where Organicell hopes to add to that field. Then, with the company pivoting to try and help tackle Covid, they […]

  • Shaping the future of ovarian cancer diagnosis with femtech

    Israeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science for the early detection of problems in women’s health. CEO and co-founder Inbal Zafir-Lavie tells pharmaphorum more. Six years ago, research scientist Inbal Zafir-Lavie tragically lost her 38-year-old sister Hava Zafir to colorectal cancer. Due to her […]

  • A problem combination?

    Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge for combination therapies. Combination therapies are now common in therapy areas like cancer. There have been cases where even if a new treatment used in combination were offered at zero cost to the NHS that it would […]

  • Delivering valuable independent medical education programmes

    In the next instalment in EPG Health’s HCP engagement series, Abhi Chakravorty looks at medical education’s new trajectory and how to build programmes that are credible, engaging and impactful. In these times of turmoil there are some reassuring constants when it comes to independent medical education (IME), which continues to be appreciated by healthcare professionals […]

  • Collaborate to simplify cancer trials and accelerate post-pandemic recovery

    How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI Scotland cancer roundtable discussion. Work to get Scotland’s cancer services back to full strength following the pandemic has already begun, and the pharmaceutical industry has pledged to play its part. […]

  • Dental implant market: Top trends bolstering industry growth

    People across the world, especially the population aged 65 years or older, are suffering from some form of a medical condition that results in tooth decay or loss. According to statistics released by the Centers for Disease Control and Prevention, around 70.1% of the population in North America was 65 years or more and was […]

  • Predicting and improving clinical trial enrolment: A problem for psychiatry

    Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates and poor patient recruitment. The reasons behind this problem, however, are rarely studied or understood. Despite this, new strategies devised over the last five years are beginning to reverse the […]

  • Evaluating methods targeting Protein-Protein Interactions

    Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them.  The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting the conventional methods. Targeting PPIs offers another potential therapeutic target for diseases with complex biological […]

  • SMA Awareness Month: How pharma and digital solutions can improve patient care

    Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord. It’s a debilitating condition that affects 1 per 8,000 to 10,000 people worldwide, impacting their ability to walk, eat, and breathe. SMA Type 1 represents an estimated 50% of all cases, for which life expectancy is less than […]

  • How to balance the patient voice atop the shifting plates of HTA

    The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances in medical science, from genomics and gene therapies to artificial intelligence (AI), have transformed the healthcare landscape, and triggered a review of NICE’s methods and processes. Consultation on the proposals […]

  • Cancer research faces uncertain post-COVID landscape

    There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding and development going forward, says The Institute of Cancer Research, London’s Paul Workman. Cancer research in the UK risks facing a “perfect storm” of stalled work and reduced funding that […]

  • Have a chat to help others through loneliness

    Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind. It’s only now, having been isolated, that we can appreciate how much small moments of contact with family and friends can mean. Bristol Myers Squibb’s Janice Creasy discusses how  and help reduce feelings […]

  • Surprise pandemic lessons for pharma

    Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a pandemic on their everyday lives and my guess is that the vast majority of us would have had little insight into what would happen. Residents of Southeast Asia who had […]

  • Health literacy in the time of COVID-19

    In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health literacy has never been more important. Impetus Digital’s Natalie Yeadon explores why. Health literacy is a complex phenomenon that involves both individuals and their local […]

  • Lessons from the first generation of cell and gene oncology trials

    Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies. ICON’s Tamie Joeckel and Brandon Fletcher take us through best-practice approaches to CGT studies and discuss what the future could hold for this exciting area. Cell and gene […]

  • Why digital doctors are crucial for the future of primary care

    Our primary care system is weathering a storm on several fronts. Demand is skyrocketing, with GPs delivering millions more appointments than in previous years and workload far outstripping pre-Covid-19 levels. Dr Dan Bunstone explores how innovation can help GPs overcome the current capacity squeeze in primary care and tackle patient backlog. Despite the misconception that general […]

  • COVID-19: We don’t need another hero

    We’ve all got used to hailing healthcare staff as heroes over the past year. Of course they deserve every ounce of admiration, even though many are uncomfortable with the adulation. But the bigger question is whether this heroic status really represents a healthy situation? Someone once advised me that, when conducting due diligence on a […]

  • Oncology R&D: the patient insights we’re still missing, and how to catch up

    Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring solutions now, and for your entire career, you have been taught that things must be done a certain way. Patient engagement is viewed by many as a nice-to-have rather than […]

  • Tackling the ‘disease of systemic racism’ in clinical trials

    A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-19. Tackling it, however, has not been easy, thanks in no small part to the reasons being as complex as they are multi-faceted. But, according to the […]

  • Digital tools key to immuno-oncology’s future: report

    If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper. The whitepaper, ‘The Role of Digital Health in Immuno-oncology Therapy Development and Adoption’ from […]

  • Virtual reality therapy: The future of chronic pain management?

    Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? pharmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre of Pain Research to find out how digital therapeutics are shaping the future of pain management. A digital software developed by Finnish drugmaker Orion is aiming to address chronic pain […]

  • COVID-19: Celltrion’s therapeutic option

    In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. pharmaphorum spoke to Kwon Ki-sung, Head of Celltrion’s R&D unit, to learn more. Celltrion’s COVID-19 therapeutic, CT-P59, is a monoclonal antibody (mAb) with activity against COVID-19. It was identified as a potential treatment through the screening of […]

  • Oncology and a year of COVID: lessons for the future

    COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, practice and education, says Lucid’s Frances O’Connor. The COVID-19 pandemic might finally be in its latter stages after a year and a half of disruption, but its […]

  • Ten tips on pharma time management

    Oliver Stohlmann’s new Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. In this first instalment he tackles managing time. A month into exiting my career of over two decades in global life-science multinationals, I’m […]

  • Medical meetings post-COVID – key lessons for pharma

    EPG Health’s Allen Wellings assesses future symposia and congress models, outlining some learnings about content and reach. COVID-19 had a huge, and very obvious, initial impact on medical congresses and symposia when 2020’s lockdowns took effect, with many events struggling to move quickly enough to a purely digital format. While many did succeed in creating […]

  • How hybrid virtual engagement is accelerating oncology communication

    COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance on real-time meetings, say experts from Within3. By making virtual meetings a necessity, COVID has forced pharma to adopt a more flexible, digitally-driven approach to stakeholder interaction – but in […]

  • Build back better: US pharma and the future of healthcare

    America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged […]

  • Build back better: US pharma and the future of healthcare

    America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged […]

  • Enabling healthcare’s digital future

    Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of expectation hangs heavy over the digital health sector. Even before COVID-19 struck, shattering established societal and healthcare norms, much was expected from start-ups that could combine health and tech. Now, […]

  • What HCPs think about health equity in cancer care

    After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in healthcare.’s Mary Kangley explores what HCPs think about health equity in cancer care. The topic rose to significance in the American Society of Clinical Oncology (ASCO) whereby they updated […]

  • Digital health developments: a new investment era for start-ups

    Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they need to take to grow their business. Digital health has come a long way in the past decade – and Kristin Milburn says that the sector could now be about […]

  • Why pharma needs a revolution in culture

    James Dempsey breaks down the misconception that culture can’t be measured, and gives tips for how companies can implement a clear culture strategy. In 2014, six years after the global financial crisis forced the world’s biggest financial institutions into some serious navel gazing, the CEO of a major international bank was despairing: “We’ve put in […]

  • NICE feedback?

    The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review its methods and processes for evaluating technologies. As part of that work, NICE is engaging widely with stakeholders, including patient organisations. Leela Barham provides an independent view of patient organisations responses to a NICE online survey and […]

  • Why pharma shouldn’t forget about sites in a post-COVID world

    The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to understand the value proposition of the technologies and methodologies adopted, says Syneos Health’s Angela Hirst. Formerly an oncology nurse and now director of Sites and Patient Services at Syneos Health’s […]

  • Taking steps towards a data-driven future for health and social care

    A new policy paper promises to make it easier for innovators and developers to build and deploy tech and AI solution. So, will it help make the vision of a data-driven health service a reality? COVID-19 “revolutionised” the health and care data space, and we have a duty to apply what we have learnt to […]

  • How digital pathways are changing healthcare

    As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance […]

  • Rare disease: industry, patients and tech join forces on diagnosis

    Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can sometimes be the most difficult part of a rare disease patient’s journey, and it’s with good reason that the process is often referred to as an ‘odyssey’ in these communities. “We’re dealing with very small populations of […]

  • Accelerating the adoption of innovation in the NHS

    Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. Scaling up the adoption of new interventions and technologies in the NHS has always been something of a challenge. But a review of approaches used by the Academic Health Science […]

  • A life sciences vision to deliver health, wealth and resilience for the UK

    The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19. What has been achieved in just 18 months is nothing […]

  • COVID-19 neutralising antibody tests – an integrated approach

    Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help life resume. Millions of tests for COVID-19 are taken worldwide every day, as they become an increasingly important tool for our return to normality. Testing programmes have been […]

  • Herd immunity is nice – but what about me?

    Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. To-date, the battle against COVID-19 has been waged largely in the field of public health, using a series of binary, black-and-white thresholds to measure progress. The number of positive cases per 100,000 people, yes/no results on PCR tests, absence or presence of […]

  • When biotech meets reality TV – Starton Therapeutics faces the Unicorn Hunters

    Starton Therapeutics is bypassing the traditional venture capital route to raise money for its transdermal delivery technology that delivers medicine through the skin. pharmaphorum hears why the company decided to appear on a new reality investment show. A big clock times a 60 second countdown as biotech CEO Pedro Lichtinger delivers an elevator pitch to […]

  • Health Innovators: Eliot Forster, F-Star

    In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the lives of patients with cancer.     About the author Dr Paul Tunnah is chief content officer and UK managing director for Healthware Group, a next-generation integrated consulting group that […]

  • Pharma’s use of synthetic biology could deliver radical innovation

    Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, […]

  • Pharma’s use of synthetic biology could deliver radical innovation

    Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, […]

  • COVID-19 vaccine development: Safety monitoring continues revolution in RWD

    From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve outcomes for patients in need. In today’s feature, Dr. Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality.  Only a year after the emergence […]

  • COVID-19 vaccine development: Safety monitoring continues revolution in RWD

    From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve outcomes for patients in need. In today’s feature, Dr. Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality.  Only a year after the emergence […]

  • Turning words into actions with patient engagement

    Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better […]

  • Turning words into actions with patient engagement

    Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better […]

  • Supporting and empowering carers to make their voices heard

    There are an estimated nine million carers in the UK, and their contributions to society, individually and as a group, are unparalleled. Nadine van Dongen and Antonella Porta remind us why carers are the unrecognised backbone of our society. Every day, carers look after some of the most vulnerable people around us, attending to their […]

  • Pandemic paves way for innovative hybrid healthcare

    While the heroic abilities of the NHS have been on display throughout the COVID-19 pandemic, the last year has also exposed the longstanding limitations and frailties of our underfunded healthcare system, says Maya Ward. With an estimated 100,000 unfilled posts and staff turnover expected to increase due to emotional exhaustion, the health service’s workforce stands […]

  • Transforming pharma R&D with a scientist-centric approach to AI & automation

    As biopharmaceutical products have become increasingly complex, both in design and in regulatory requirements, we need a new way of working. Markus Gershater looks at how automation and artificial intelligence (AI) can transform pharma R&D. Due to increasing complexity in R&D, pharma teams are under pressure to drive down costs and speed up time to […]

  • A roadmap for adopting New Science 

    The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships drive innovation to address a common need. Can the biopharma industry step up again to shatter industry orthodoxy and create new pathways for innovation, access, and affordability? The adoption of […]

  • How the patient voice is becoming vital for drug approval

    Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read below for […]

  • Keeping clinical trial data safe – handling cybersecurity in a risky world

    The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the increased complexity and involvement of different parties, exposes manufacturers to heightened threat levels. Abel Archundia discusses how COVID-19 has highlighted the importance of securing clinical trials against cyber threats. A process that historically would have […]

  • Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

    As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn, explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are […]

  • Ensuring accessibility: Crossing the digital divide in healthcare

    “Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left behind as the world embraces digital healthcare say leading user experience, voices. The experts discussed the benefits and merits of co-creation during a session on bridging the digital divide, held […]

  • Experts discuss the field force’s customer-centric future

    The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that. In a recent pharmaphorum webinar, in partnership with Axtria, commercialisation experts from across the industry discussed how the right field force training and execution in combination with […]

  • “A long way to go” for digital health reimbursement

    A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: In many ways, the healthcare sector is still wrestling […]

  • Value-based healthcare: Pandemic learnings and future musings

    In the second part of our series from the ‘Patient Experience: Empathy and Innovation’ Digital Summit, we look at what COVID-19 can teach us about designing truly value-based healthcare.  Discussions of value-based healthcare provider contracts are often technical and far removed from the patient – but COVID has given us a chance to connect the […]

  • Time for a NICE change

    The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. […]

  • What HCPs think about blood clots linked to COVID-19 vaccines

    In the latest edition of What HCPs Think,’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. The formation of blood clots is a necessary process in order for the body to repair damage caused by injury and to slow down bleeding. However, when blood clots form inappropriately, […]

  • BIO-Europe Spring Digital: Nerida Scott, J&J’s EMEA Innovation Head

    At this year’s BIO-Europe Spring Digital, pharmaphorum founder Dr. Paul Tunnah participated in an ‘In conversation’ chat with Nerida Scott, head of Johnson & Johnson Innovation, EMEA. Nerida discussed the latest trends in healthcare and how they’ve influenced Johnson & Johnson Innovation’s (JJI’s) approach to collaboration. She highlighted the importance of digital solutions and data […]

  • Are microtaggants the key to making medicines smarter?

    Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. The dramatic rise in online drug sales during the COVID-19 pandemic has increased the supply of counterfeit drugs, and many companies are now considering the addition of on-dose authentication for high-risk or high-value products. To implement […]

  • Pharma’s post-COVID prospects: the pharmaphorum podcast

    In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season. Meade talked about the prospects for the industry as the UK and other economies beginning to recover from the devastating pandemic. He discussed how COVID vaccines have […]

  • Closing the feedback loop to drive patient experience improvements

    Is collecting near real time data the key to unlocking improvements in patient experience and national benchmarking? Small things can go a long way in terms of improving patient experience, but healthcare facilities cannot fix what they don’t know is broken. In the first of our series of articles from the Patient Experience: Empathy and […]

  • Rethinking access barriers to innovation

    Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. This article appears in our digital magazine Deep Dive: Market Access 2021. Read on […]

  • How diversity can help life sciences advance its lifesaving solutions

    Paula Parfitt discusses the importance of workplace diversity and how life science companies can build a thriving, diverse workforce. Diversity, equity and inclusion (D, E & I) is a sensible business choice with significant commercial benefits. A homogenous workforce has a smaller pool of collective experience, meaning that when problems arise, collective creativity and innovation […]

  • New Cell & Gene Therapy Collective seeks to boost UK adoption

    The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to wider adoption. These challenges often arise because these therapies go through the same value assessment processes as less complex medicines, and the infrastructure […]

  • AI, big data and real world evidence – the challenges and opportunities

    Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. A recent pharmaphorum webinar, held in partnership with Savana and BREATHE – the Health Data Research Hub for Respiratory Health, heard that RWE is also accelerating the development of new and innovative therapies […]

  • AI meets RWE: The future of drug assessment?

    Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma and regulators. This article appears in out digital magazine Deep Dive: Market Access 2021. Read below for a preview: Real world evidence (RWE) is rapidly evolving. Having gone from being […]

  • What is modular content and why do pharma marketers need it NOW?

    Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. It is a newer concept for pharma marketers, however, who are now turning to modular solutions in response […]

  • Listening to ultra-rare disease communities

    When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare diseases, PTC Therapeutics is familiar with the challenges. The company prides itself on a patient-centric approach to treatment but there can be significant hurdles in patients accessing potentially life-changing treatments. […]

  • Arecor heads for London Stock Exchange with drug reformulation strategy

    Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients.  Arecor Therapeutics is the latest company aiming to take advantage of the “feelgood” factor in the biotech sector, which […]

  • Report calls for better work culture in UK research

    Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. From the Oxford vaccine to the RECOVERY trial, all eyes have been on the triumph of British science in recent months. But future success is at risk if we do not create a […]

  • How to improve payer engagement with tailored value communication

    Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic areas. However, value can mean different things to different payers. In this article, Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing […]

  • The Online Safety Bill: a step towards digitally safe mental health support

    The UK government’s Online Safety Bill has been a hot and contentious topic of discussion over the past year, but last week it was finally announced and included in the Queen’s Speech. For Mental Health Awareness Month, Tim Barker looks at why a new bill could be a step towards digitally safe mental health support.  […]

  • Key insights for a successful first-time product launch

    Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning and an agile approach, they can be more successful than they realise, says Veeva’s Ian Hale. He takes us through the challenges of a successful launch and explains what pre-commercial […]

  • Designing HCP engagement for the next normal

    Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Restrictions to in-person face-to-face interactions have resulted in increased use of remote and digital channels. Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change, and its […]

  • How will NICE fare in a post-Brexit world?

    NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. This article appears in our digital magazine, Deep Dive: Market Access […]

  • Health Innovators: Teresa Arroyo-Gallego, nQ Medical

    In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist at artificial intelligence technology company nQ Medical. As a researcher in the biomedical engineering lab of the Massachusetts Institute of Technology (MIT), Teresa leads a team developing the neuroQWERTY technology to detect early signs of motor decline in […]

  • Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimab

    Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab. In an interview with pharmaphorum’s news editor Richard Staines, chief operating officer Arnout Ploos van Amstel revealed how the biotech and its “mystery CEO” managed to swoop for the drug ahead of big pharma rivals. […]

  • Why health tech is a win for mental health

    For Mental Health Awareness Week (10 May 2021 – 16 May 2021) myGP discusses the benefits of the healthcare system becoming digitised and the impact this will have on mental health care.  The UK government has pledged an ambitious programme of revolutionising mental health over the next three years, seeing all mental health service providers […]

  • 4 ways to embed data-driven best practice in pharma HCP communications

    Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharma companies to maintain up-to-date customer data. Over the 12 months to December 2020 the number of global Veeva CRM Engage Meetings increased sixfold, while those held in Europe saw an eight-fold increase – with 200,000 remote […]

  • Research predicts the post-COVID landscape for HCP engagement

    IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes. This article appears in full in Deep Dive: Market Access 2021. Read a preview below: Recent ChannelDynamics data from IQVIA shows that while there has been a marked […]

  • Is digital mental health the key to tackling a deepening crisis?

    In an exclusive feature for pharmaphorum, British Liberal Democrat politician, solicitor and mental health campaigner Sir Norman Lamb discusses why digital mental health services can help tackle the escalating mental health crisis. The COVID-19 pandemic has had a severe negative effect on the population’s mental health across the globe. We know that government measures like […]

  • A year on: pandemic driven trends in HCP engagement

    IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears in full in this month’s Deep Dive digital magazine on Market Access. Here is a preview: As we reach the end of the first quarter of 2021, our customers continue […]

  • How a lack of mental health diagnosis is affecting young men

    As lockdown gradually eases, things are starting to look up but the lasting impact COVID-19 has had on our wellbeing remains. During Mental Health Awareness Month we look at the mental health stigma amongst men. To say we’re in the midst of a mental health crisis is not an exaggeration. Mental health concerns have been […]

  • Why relationships are key in rare disease patient engagement

    Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperiome’s Jeremy Edwards. It is difficult to get data on rare diseases and the people who live with them by their very nature. […]

  • Tackling diabetes & ALS with cell therapy

    Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes. Catherine Longworth spoke with Kadimastem’s head of diabetes research, Kfir Molakandov to find out more. In the 1990s, when the first transplant of islets took place, […]

  • Creating a global life sciences superpower from the lessons of COVID

    It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “life sciences superpower”, says health secretary Matt Hancock. The UK’s life sciences industry has “achieved in months what usually takes years” – and in doing so has built a solid foundation […]

  • Hidden compliance risks for life sciences companies

    The life sciences history industry has some unique challenges when it comes to compliance. But if you think third party compliance risks are bad, don’t take your eye off fourth and fifth parties, says Allan Matheson. Early life science pioneers in foreign markets earned a reputation for lax ethical behaviour, making them a prime target […]

  • Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

    Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce […]

  • Deep Dive: Market Access

    It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. […]

  • Not just COVID-19 vaccines: 5 things that cause blood clots

    Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the most common causes of blood clots and how we can prevent them. Over 11 million doses of COVID-19 vaccines have been given across the UK, with blood clotting observed […]

  • Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

    Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care. Founder and CEO Konstantin Mehl spoke to pharmaphorum’s news editor Richard Staines about why these treatments will be in demand as the world emerges from the pandemic. To say that […]

  • The role of data science and text mining in the search for new therapies

    Today, most drug discovery programmes begin with the identification and validation of disease modifying biological targets. The primary way to uncover these targets is through searching and reviewing published scientific literature. Eric Gilbert explores how data science techniques like text mining are speeding up research into areas such as pancreatic cancer. The increasing rate of […]

  • Can your typing patterns reveal if you have Alzheimer’s?

    The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now the team behind it is looking to expand into the notoriously-difficult area of dementia. Teresa Arroyo-Gallego tells us about the science behind the technology and how the team hopes to reshape cognitive screening.  While many disease areas […]

  • AI is having a productive time in pharma and healthcare

    Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the Plateau of Productivity. After the COVID-powered digital transformations of both pharma and healthcare, there can be little doubt that artificial intelligence is already having a productive time across our sector. […]

  • Collaboration is key to advancing cell therapy research

    Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company works with researchers and physicians across Europe to expand patient access to cell therapy. This thought leadership series has been paid and developed by Kite, a Gilead Company. Cell therapy is a treatment involving the genetic modification […]

  • Big data and cell therapy development: the pharmaphorum podcast

    In the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr Darrin Disley, who’s the CEO of Mogrify. The UK biotechnology company is aiming to transform the development of cell therapies using a systematic direct cell conversion & maintenance platform powered by big-data. Darrin discusses the story behind Mogrify’s technology and his […]

  • What comes next: digital transformation in B2B life sciences sales

    As the contours of a post-pandemic world begin to take shape, those working B2B sales in the life sciences acknowledge that the industry must adapt to some permanent shifts. Mert Yentur looks at what is next for the industry. Even prior to COVID-19, sales teams reckoned with traditional online-only CRM systems that didn’t align well […]

  • Clive Dix: Rebuilding UK biotech

    UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. In an interview with pharmaphorum’s news editor Richard Staines, he reflected on the last year and how it could prove to be […]

  • Three pillars of post-pandemic launch excellence

    IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address in 2021. It is undeniable that 2020 was a particularly challenging year to launch non-COVID innovative prescription medicines. The launch environment was directly impacted by the COVID-19 pandemic, which hit […]

  • Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

    When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides itself on having an open, collaborative, “science first” approach to help ensure breakthrough discoveries have the very best chance of long-term success in bringing new treatment options to patients worldwide. “Our mission is to turn innovative science […]

  • GDPR represents an “urgent threat” to the EU’s research leadership role

    More than 5,000 collaborative studies were thwarted by GDPR rules in 2019 – but is there a way to protect sensitive data while still allowing international health research to thrive?  A coalition of European academy networks has called upon European Union (EU) leaders to rethink how General Data Protection Regulation (GDPR) rules are applied to […]

  • Cytisinicline – the solution to stop smoking?

    Whether present in electronic or combustible cigarettes, nicotine is a highly addictive substance. Dr Cindy Jacobs, chief medical officer of Achieve Life Sciences discusses the potential of cytisinicline therapy for smoking cessation.  Although e-cigarettes are considered a less dangerous alternative to combustible cigarettes, they can still result in, or sustain, nicotine addiction, for which the […]

  • The power of communication: engaging diverse groups in healthcare

    Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society – especially in healthcare. Page & Page’s Lisa Jane Lishman outlines why communication and the strategies behind it need to be more personal to ensure that people […]

  • The next generation of immunotherapy? Innate Pharma targets NK cells

    Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer. Catherine Longworth spoke to CEO Mondher Mahjoubi to find out the science behind this next generation of immunotherapies.  Founded in 1999, Marseille-based company Innate Pharma is on a mission to develop immunotherapies that take advantage […]

  • Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

    Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. He spoke to pharmaphorum’s news editor Richard Staines to outline his plans to create a European biotech powerhouse.  The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories. Under the […]

  • What Is The Best Way to Incentivise a Digital-First Sales Team?

    Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be very ineffective. If clearly defined they will get you results, but if not, they can just reinforce the wrong behaviours. The difficulty is to define the right ones. Bottomline is […]